Literature DB >> 20040581

Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences.

Deepak Dalvie1, Chenghong Zhang, Weichao Chen, Teresa Smolarek, R Scott Obach, Cho-Ming Loi.   

Abstract

Excretion and metabolism of zoniporide were investigated in humans after intravenous infusion of [(14)C]zoniporide at an 80-mg dose. Bile was the primary route of excretion because 57% of dose was recovered in the feces after intravenous infusion. Zoniporide was primarily cleared via metabolism in humans. 2-Oxozoniporide (M1) was the major excretory and circulating metabolite in humans and was catalyzed by aldehyde oxidase (K(m) of 3.4 microM and V(max) of 74 pmol/min/mg protein). Metabolites M2 (17% of the dose) and M3 (6.4% of circulating radioactivity), in which the guanidine moiety was hydrolyzed to a carboxylic acid, were also detected in human feces and plasma, respectively, suggesting that hydrolysis was another route of metabolism of zoniporide in humans. The metabolism and excretion of [(14)C]zoniporide in rats and dogs were also evaluated. As in humans, bile was the primary route of excretion of the radiolabeled material in both species, and metabolism was the primary route of clearance. A comparison of plasma metabolites showed that for M3, rats had a higher concentration than human or dog. M1 was absent in dog and present in human and rat plasma at comparable levels, whereas comparison of excreta showed that the total body burden of M1 was greater in rat than that in human. No further evaluation of M2 was considered because it was detected only in the human fecal extracts. Hence, no further toxicological evaluation of the three human metabolites was undertaken.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20040581     DOI: 10.1124/dmd.109.030783

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

Review 1.  Xenobiotica-metabolizing enzymes in the skin of rat, mouse, pig, guinea pig, man, and in human skin models.

Authors:  F Oesch; E Fabian; Robert Landsiedel
Journal:  Arch Toxicol       Date:  2018-06-18       Impact factor: 5.153

Review 2.  Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.

Authors:  Upendra A Argikar; Philip M Potter; J Matthew Hutzler; Punit H Marathe
Journal:  AAPS J       Date:  2016-08-05       Impact factor: 4.009

3.  Role of Molybdenum-Containing Enzymes in the Biotransformation of the Novel Ghrelin Receptor Inverse Agonist PF-5190457: A Reverse Translational Bed-to-Bench Approach.

Authors:  Sravani Adusumalli; Rohitash Jamwal; R Scott Obach; Tim F Ryder; Lorenzo Leggio; Fatemeh Akhlaghi
Journal:  Drug Metab Dispos       Date:  2019-06-10       Impact factor: 3.922

4.  A novel in vitro allometric scaling methodology for aldehyde oxidase substrates to enable selection of appropriate species for traditional allometry.

Authors:  Rachel D Crouch; J Matthew Hutzler; J Scott Daniels
Journal:  Xenobiotica       Date:  2017-03-10       Impact factor: 1.908

5.  Cross-reactivity of acid-sensing ion channel and Na⁺-H⁺ exchanger antagonists with nicotinic acetylcholine receptors.

Authors:  Julio Santos-Torres; Marta A Ślimak; Sebastian Auer; Inés Ibañez-Tallon
Journal:  J Physiol       Date:  2011-09-12       Impact factor: 5.182

6.  Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.

Authors:  Hengmiao Cheng; Chunze Li; Simon Bailey; Sangita M Baxi; Lance Goulet; Lisa Guo; Jacqui Hoffman; Ying Jiang; Theodore Otto Johnson; Ted W Johnson; Daniel R Knighton; John Li; Kevin K-C Liu; Zhengyu Liu; Matthew A Marx; Marlena Walls; Peter A Wells; Min-Jean Yin; Jinjiang Zhu; Michael Zientek
Journal:  ACS Med Chem Lett       Date:  2012-11-07       Impact factor: 4.345

7.  The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5.

Authors:  Ryan D Morrison; Anna L Blobaum; Frank W Byers; Tammy S Santomango; Thomas M Bridges; Donald Stec; Katrina A Brewer; Raymundo Sanchez-Ponce; Melany M Corlew; Roger Rush; Andrew S Felts; Jason Manka; Brittney S Bates; Daryl F Venable; Alice L Rodriguez; Carrie K Jones; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Kyle A Emmitte; J Scott Daniels
Journal:  Drug Metab Dispos       Date:  2012-06-18       Impact factor: 3.922

8.  Time Course of Aldehyde Oxidase and Why It Is Nonlinear.

Authors:  Armina Abbasi; Erickson M Paragas; Carolyn A Joswig-Jones; John T Rodgers; Jeffrey P Jones
Journal:  Drug Metab Dispos       Date:  2019-02-20       Impact factor: 3.922

Review 9.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

10.  Site-Directed Mutagenesis at the Molybdenum Pterin Cofactor Site of the Human Aldehyde Oxidase: Interrogating the Kinetic Differences Between Human and Cynomolgus Monkey.

Authors:  Armina Abbasi; Carolyn A Joswig-Jones; Jeffrey P Jones
Journal:  Drug Metab Dispos       Date:  2020-10-05       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.